Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline

Donal P McLornan; Anna L Godfrey; Anna Green; Rebecca Frewin; Siamak Arami; Jessica Brady; Nauman M Butt; Catherine Cargo; Joanne Ewing; Sebastian Francis; Mamta Garg; Claire Harrison; Andrew Innes; Alesia Khan; Steve Knapper; Jonathan Lambert; Adam Mead; Andrew McGregor; Pratap Neelakantan; Bethan Psaila; Tim C P Somervaille; Claire Woodley; Jyoti Nangalia; Nicholas C P Cross; Mary Frances McMullin; BSH Committee

doi:10.1111/bjh.19164

Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline

Donal P McLornan, Anna L Godfrey, Anna Green, Rebecca Frewin, Siamak Arami, Jessica Brady, Nauman M Butt, Catherine Cargo, Joanne Ewing, Sebastian Francis, Mamta Garg, Claire Harrison, Andrew Innes, Alesia Khan, Steve Knapper, Jonathan Lambert, Adam Mead, Andrew McGregor, Pratap Neelakantan, Bethan PsailaTim C P Somervaille, Claire Woodley, Jyoti Nangalia, Nicholas C P Cross, Mary Frances McMullin, BSH Committee

School of Medicine, Dentistry and Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

5 Downloads (Pure)

Abstract

This document represents an update of the British Society for Haematology (BSH) guideline on myelofibrosis (MF) first published in 2012 and updated in 2015.1 This guideline aims to provide healthcare professionals with clear guidance on the diagnosis and prognostic evaluation of primary myelofibrosis (PMF), as well as post-polycythaemia vera myelofibrosis (post-PV MF) and post-essential thrombocythaemia myelofibrosis (post-ET MF). A section on prefibrotic MF is also included. A separate BSH Guideline covers the management of MF and is published alongside this guideline.

Original language	English
Number of pages	11
Journal	British Journal of Haematology
Early online date	06 Nov 2023
DOIs	https://doi.org/10.1111/bjh.19164
Publication status	Early online date - 06 Nov 2023

Access to Document

10.1111/bjh.19164Licence: Unspecified

Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline
© 2023 British Society for Haematology and John Wiley & Sons Ltd. This work is made available online in accordance with the publisher’s policies. Please refer to any applicable terms of use of the publisher.
Accepted author manuscript, 406 KBLicence: Unspecified

Cite this

McLornan, D. P., Godfrey, A. L., Green, A., Frewin, R., Arami, S., Brady, J., Butt, N. M., Cargo, C., Ewing, J., Francis, S., Garg, M., Harrison, C., Innes, A., Khan, A., Knapper, S., Lambert, J., Mead, A., McGregor, A., Neelakantan, P., ... BSH Committee (2023). Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline. British Journal of Haematology. Advance online publication. https://doi.org/10.1111/bjh.19164

@article{4b481740cf43431fb7f7bf0285b4e1e3,

title = "Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline",

abstract = "This document represents an update of the British Society for Haematology (BSH) guideline on myelofibrosis (MF) first published in 2012 and updated in 2015.1 This guideline aims to provide healthcare professionals with clear guidance on the diagnosis and prognostic evaluation of primary myelofibrosis (PMF), as well as post-polycythaemia vera myelofibrosis (post-PV MF) and post-essential thrombocythaemia myelofibrosis (post-ET MF). A section on prefibrotic MF is also included. A separate BSH Guideline covers the management of MF and is published alongside this guideline.",

author = "McLornan, {Donal P} and Godfrey, {Anna L} and Anna Green and Rebecca Frewin and Siamak Arami and Jessica Brady and Butt, {Nauman M} and Catherine Cargo and Joanne Ewing and Sebastian Francis and Mamta Garg and Claire Harrison and Andrew Innes and Alesia Khan and Steve Knapper and Jonathan Lambert and Adam Mead and Andrew McGregor and Pratap Neelakantan and Bethan Psaila and Somervaille, {Tim C P} and Claire Woodley and Jyoti Nangalia and Cross, {Nicholas C P} and McMullin, {Mary Frances} and {BSH Committee}",

year = "2023",

month = nov,

day = "6",

doi = "10.1111/bjh.19164",

language = "English",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley & Sons Inc.",

}

McLornan, DP, Godfrey, AL, Green, A, Frewin, R, Arami, S, Brady, J, Butt, NM, Cargo, C, Ewing, J, Francis, S, Garg, M, Harrison, C, Innes, A, Khan, A, Knapper, S, Lambert, J, Mead, A, McGregor, A, Neelakantan, P, Psaila, B, Somervaille, TCP, Woodley, C, Nangalia, J, Cross, NCP, McMullin, MF & BSH Committee 2023, 'Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline', British Journal of Haematology. https://doi.org/10.1111/bjh.19164

TY - JOUR

T1 - Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline

AU - McLornan, Donal P

AU - Godfrey, Anna L

AU - Green, Anna

AU - Frewin, Rebecca

AU - Arami, Siamak

AU - Brady, Jessica

AU - Butt, Nauman M

AU - Cargo, Catherine

AU - Ewing, Joanne

AU - Francis, Sebastian

AU - Garg, Mamta

AU - Harrison, Claire

AU - Innes, Andrew

AU - Khan, Alesia

AU - Knapper, Steve

AU - Lambert, Jonathan

AU - Mead, Adam

AU - McGregor, Andrew

AU - Neelakantan, Pratap

AU - Psaila, Bethan

AU - Somervaille, Tim C P

AU - Woodley, Claire

AU - Nangalia, Jyoti

AU - Cross, Nicholas C P

AU - McMullin, Mary Frances

AU - BSH Committee

PY - 2023/11/6

Y1 - 2023/11/6

N2 - This document represents an update of the British Society for Haematology (BSH) guideline on myelofibrosis (MF) first published in 2012 and updated in 2015.1 This guideline aims to provide healthcare professionals with clear guidance on the diagnosis and prognostic evaluation of primary myelofibrosis (PMF), as well as post-polycythaemia vera myelofibrosis (post-PV MF) and post-essential thrombocythaemia myelofibrosis (post-ET MF). A section on prefibrotic MF is also included. A separate BSH Guideline covers the management of MF and is published alongside this guideline.

AB - This document represents an update of the British Society for Haematology (BSH) guideline on myelofibrosis (MF) first published in 2012 and updated in 2015.1 This guideline aims to provide healthcare professionals with clear guidance on the diagnosis and prognostic evaluation of primary myelofibrosis (PMF), as well as post-polycythaemia vera myelofibrosis (post-PV MF) and post-essential thrombocythaemia myelofibrosis (post-ET MF). A section on prefibrotic MF is also included. A separate BSH Guideline covers the management of MF and is published alongside this guideline.

U2 - 10.1111/bjh.19164

DO - 10.1111/bjh.19164

M3 - Article

C2 - 37932932

SN - 0007-1048

JO - British Journal of Haematology

JF - British Journal of Haematology

ER -

Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline

Abstract

Access to Document

Fingerprint

Cite this